Proteostasis Therapeutics News Releases http://ir.proteostasis.com/ Proteostasis Therapeutics News Releases en Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-present-2019-rbc-capital-markets BOSTON , May 15, 2019 /PRNewswire/ --  Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today Wed, 15 May 2019 08:00:00 -0400 Proteostasis Therapeutics News Releases 8466 Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-appoints-dr-badrul-chowdhury-former BOSTON , May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today Mon, 13 May 2019 08:00:00 -0400 Proteostasis Therapeutics News Releases 8431 Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-reports-first-quarter-2019-financial BOSTON , May 8, 2019 /PRNewswire/ --  Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today Wed, 08 May 2019 17:15:00 -0400 Proteostasis Therapeutics News Releases 8401 Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-broad-new-dataset Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p Mon, 25 Mar 2019 07:00:00 -0400 Proteostasis Therapeutics News Releases 8371 Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-appoints-david-arkowitz-board BOSTON , March 7, 2019 /PRNewswire/ --  Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today Thu, 07 Mar 2019 07:00:00 -0500 Proteostasis Therapeutics News Releases 8336 Proteostasis Selected to Join European Consortium to Pioneer Personalized Medicine in Cystic Fibrosis http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-selected-join-european-consortium-pioneer PTI-428, PTI-801 and PTI-808 Testing Underway in Organoids from CF Patients, with Potential for Clinical Data in 2020 HIT CF Project Funded by the European Union's Horizon 2020 Research and Innovation Programme BOSTON , Feb. 27, 2019 /PRNewswire/ --  Proteostasis Therapeutics, Inc. Wed, 27 Feb 2019 08:00:00 -0500 Proteostasis Therapeutics News Releases 8296 Proteostasis Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-present-8th-annual-svb-leerink-global BOSTON , Feb. 20, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today Wed, 20 Feb 2019 07:00:00 -0500 Proteostasis Therapeutics News Releases 8276 Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-appoints-emmanuel-dulac-and-kim BOSTON , Feb. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today Wed, 06 Feb 2019 08:00:00 -0500 Proteostasis Therapeutics News Releases 8231 Proteostasis Therapeutics Provides Clinical Enrollment Update http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-provides-clinical-enrollment-update Proprietary Triplet Successfully Completes First Cohort and Proceeds with Higher Dose Testing, Study Remains Blinded Company to Report Full Results of All Planned Proprietary Combination Studies in the First Quarter of 2019 Add-on Combination Studies with PTI-801 and PTI-428 on top SYMDEKO® Remain Thu, 20 Dec 2018 16:30:00 -0500 Proteostasis Therapeutics News Releases 8151 Proteostasis Therapeutics Announces Global License Agreement with Genentech http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-global-license-agreement Agreement Covers Small Molecule Modulators of the Cellular Proteostasis Network BOSTON , Dec. 17, 2018 /PRNewswire/ --  Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic Mon, 17 Dec 2018 07:00:00 -0500 Proteostasis Therapeutics News Releases 8141